Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications

Recent Patents on Biotechnology

Volumn 1, Issue 2, 2007, Pages 113-122

  Donovan, David M ^a  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

antibiotic resistance; Bacteriophage; endolysin; holin; lysin; lysostaphin; lysozyme; peptidoglycan hydrolase

Indexed keywords

ANTIBIOTICS; BACTERIA; CELL MEMBRANES; CYTOLOGY; GENE EXPRESSION; HYDROLASES; LIPID BILAYERS;

ANTIBIOTICS RESISTANCE; CELL WALLS; DEGRADING ENZYMES; ENDOLYSIN; HOLIN; LYSIN; LYSOSTAPHIN; PEPTIDOGLYCAN HYDROLASE; PEPTIDOGLYCANS; STRUCTURAL COMPONENT;

BACTERIOPHAGES;

ANTIINFECTIVE AGENT; ENDOLYSIN; LYSOZYME; PEPTIDOGLYCAN; PROTEINASE; VIRUS PROTEIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIUM; CELL WALL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATENT; REVIEW; VIROLOGY;

ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; CELL WALL; DRUG RESISTANCE, BACTERIAL; ENDOPEPTIDASES; HUMANS; MURAMIDASE; PATENTS AS TOPIC; PEPTIDOGLYCAN; VIRAL PROTEINS;

EID: 51349138721     PISSN: 18722083     EISSN: 22124012     Source Type: Journal    
DOI: 10.2174/187220807780809463     Document Type: Article

References (190)

1. Foucault C, Brouqui P. How to fight antimicrobial resistance. FEMS Immunol Med Microbiol 2006; [Epub ahead of print].
2. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 2006; 24(12): 1508-11.
3. Kutter, E. Pharamcology of natural medicines, phage therapy: bacteriophages as nautural self-limiting antibiotics; edited by J. Pizzorno and M. Murray, published by Churchill/Livingstone (2005) [http://www. evergreen.edu/phage/docs/textbookofnaturalmedicinephage.pdf].
4. Ho K. Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspect Biol Med 2001; 44(1): 1-16.
5. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 2006; 24(5): 212-218.
6. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006; 296(1): 5-14.
7. Mathur MD, Vidhani S, Mehndiratta PL. Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India 2003; 51: 593-96.
8. Kutter, E and Sulakvelidze, A. Bacteriophages biology and applications, CRC Press 2005.
9. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128(2): 307-18.
10. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129(8): 2659-75.
11. Public Health Focus: surveillance, prevention and control of nosocomial infections. MMWRM orb Mortal Wkly Rep 1992; 41: 783-87.
12. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6(4): 428-42.
13. Fraser VJ. Starting to learn about the costs of nosocomial infections in the new millennium: where do we go from here? Infect Control Hosp Epidemiol 2002; 23(4): 174-76.
14. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
15. Anonymous. Staphylococcus aureus resistant to vancomycin-United States. MMWR 2002; 51: 565-6.
16. Anonymous. Vancomycin-resistant Staphylococcus aureus New York, MMWR Morb Mortal Wkly Rep 2004; 53: 322-23.
17. Carlton RM. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) 1999; 47(5): 267-74.
18. Walsh, S.M., Shah, A., Mond, J.J.: WO2004052308 A2 (2004).
19. Ghanbari, H.A., Averback, P.: US20050260171A1 (2005); US20056942858 (2005).
20. Jayasheela, M., Sriram, B., Padmanabhan, S.: WO05046579 (2005).
21. Morris, J. G., Sulakvelidze, A., Alavidze, Z., Pasternack, G. R., Brown, T.C.: US20040247569 (2004).
22. Jian, H.: CN1690194 (2005).
23. Wang, H. J.: CN1699559 (2005).
24. Lenihan, N., Holland, M.A.: CA2523693 A1 (2004).
25. Merril, C. R., Carlton, R.M., Adhya, S.: WO069269 (2000).
26. Amorena B, Gracia E, Monzon M, et al. Antibiotic susceptibility assay for Staphylococcus aureus in biofilms developed in vitro. J Antimicrob Chemother 1999; 44(1): 43-55.
27. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov 2003; 2(2): 114-22.
28. Kong KF, Vuong C, Otto M. Staphylococcus quorum sensing in biofilm formation and infection. Int J Med Microbiol 2006; 296(2-3): 133-9.
29. Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ, Blevins JS, Smeltzer MS. Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 2004; 186(14): 4665-84.
30. Resch A, Rosenstein R, Nerz C, Gotz F. Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions. Appl Environ Microbiol 2005; 71(5): 2663-76.
31. Resch A, Leicht S, Saric M, Pasztor L, Jakob A, Gotz F, Nordheim A. Comparative proteome analysis of Staphylococcus aureus biofilm and planktonic cells and correlation with transcriptome profiling. Proteomics 2006; 6(6): 1867-77.
32. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003; 1(4): 667-83.
33. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 2004; 230(1): 13-38.
34. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45(4): 999-1007.
35. Cerca N, Martins S, Cerca F, Jefferson KK, Pier GB, Oliveira R, Azeredo J. Comparative assessment of antibiotic susceptibility of coagulase-negative Staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J Antimicrob Chemother 2005; 56(2): 331-36.
36. Rachid S, Ohlsen K, Witte W, Hacker J, Ziebuhr W. Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesin expression in biofilm-forming Staphylococcus epidermidis. Antimicrob Agents Chemother 2000; 44(12): 3357-63.
37. Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol 2006; 306: 251-58.
38. Weiner, R, Langille S and Quintero, E. Structure, function and immuno-chemistry of bacterial exopolysaccharides. J Ind Microbiol 1995; 15: 339-346.
39. Sharp, R., Huges, G., Hart, A., Walker, J.T.: US20060140911A1 (2006).
40. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50(4): 1268-75.
41. Sillankorva S, Oliveira R, Vieira MJ, Sutherland IW, Azeredo J. Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 2004; 20(3): 133-8.
42. Sharma M, Ryu JH, Beuchat LR. Inactivation of Escherichia coli O157:H7 in biofilm on stainless steel by treatment with an alkaline cleaner and a bacteriophage. J Appl Microbiol 2005; 99(3): 449-59.
43. Schaak, D.L.: US2004 6759229 (2004).
44. Pasechnik, V.A., Roberts, A.D.G., Sharp, R.J.: US 20036660264 (2003).
45. Larocca, D., Baird, A., Johnson, W.: US20067148202 (2006).
46. Yacoby, I., Ron, E.Z., Shabat, D., Shamis, M., Benhar, I.: WO06095345 (2006).
47. Bermudes, D.G., King, I.C., Clairmon, C.A.: US20040219169 A1 (2004).
48. Blasi, U., Hohenadl, C.: WO06008312 A1 (2006).
49. Ramachandran, J., Padmanabhan, S., Sriram, B.: WO04046319 A2 (2004).
50. Gorski, A., Lipinski, T., Syper, D., Weber-Dabrowska, B.: WO04045645 (2004).
51. Gangagen Life Sciences, Inc.: WO06047872 A1 (2006).
52. Gangagen Life Sciences, Inc.: WO06047871 A1 (2006).
53. Mandeville, R., Allain, B., Murthy, K.; US2004040241825 (2004).
54. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973; 246(5430): 221-3.
55. Merril, C.R., Carlton, R.M., Adhya, S.L.: US050063957 A1 (2005).
56. Gasanov U, Hughes D, Hansbro PM. Methods for the isolation and identification of Listeria spp. and Listeria monocytogenes: a review. FEMS Microbiol Rev 2005; 29(5): 851-75.
57. Miller, S.: US20067087376 (2006).
58. Rees, J.: WO06105504A1 (2006).
59. Voorhees, K., Rees J., Wheeler, J.: WO05001475A2 (2005).
60. Voorhees, K., Rees J., Wheeler, J., Madonna, A.: US20050003346A1 (2005).
61. Wheeler, J., Rees, J., Gaisford, G.: WO06083292A2 (2006).
62. Azzazy HM, Highsmith WE Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002; 35(6): 425-45.
63. Mullen LM, Nair SP, Ward JM, Rycroft AN, Henderson B. Phage display in the study of infectious diseases. Trends Microbiol 2006; 14(3): 141-7.
64. Siegel, D.: US20056979534 (2005).
65. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 1999; 18(9-10): 765-77.
66. Pasternack, G.R., Sulakvelidze, A., Brown, T.: WO 05027829 (2005).
67. Ramachandran, J., Padmanabhan, S, Sriram, B.: US 2005 6,896,882 (2005); US 20056,913,753 (2005); US20067087226 (2006).
68. Ramachandran, J., Padmanabhan, S, Sriram, B.: US 2005129711 (2005).
69. March, J.B.: US20067128916 (2006).
70. March, J.B.: WO04030694 (2004).
71. Rao, V.: WO05058006 (2005).
72. Wertz, C.E., Ryde, N.P.: WO03066021A2 (2003).
73. Scalzo, H., Fischer, J.A., Rothenburger, S.: US20040220614 (2004).
74. Sulakvelidze, A., Morris, J.G. Jr., Alavidze, Z., Pasternack, GR, Brown, T.C.: US6699701 (2004).
75. Sulakvelidze, A., Morris, J.G. Jr., Alavidze, Z., Pasternack, GR, Brown, T.C.: US200509244383A1 (2005).
76. Donlan, R. M., Curtin, J.J.: WO06063176A2 (2006).
77. Binnewies TT, Motro Y, Hallin PF, et al. Ten years of bacterial genome sequencing: comparative-genomics-based discoveries. Funct Integr Genomics 2006; [Epub ahead of print].
78. Kwan T, Liu J, DuBow M, Gros P, Pelletier J. The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci USA 2005; 102(14): 5174-9.
79. Pelletier, J., Gros, P., DuBow, M.: US20046737508 (2004); US 20046783930 (2004); US20066982153 (2006); US20067101969 (2006).
80. Stewart, C.R., Shamoo, A.Y.: US2005054571 (2005).
81. Werner, M.H., Lambert, L.J.: US20066994985 (2006).
82. Bergeron, D., Dehbi, M., Dubow, M., Gros, Ph., McCarty, J., Pelletier, J.: US20040157314A1 (2004).
83. Delbruck, M. The growth of bacteriophage and lysis of the host. J Gen Physiol 1940; 23: 643-660.
84. Moak M, Molineux IJ. Role of the Gp16 lytic transglycosylase motif in bacteriophage T7 virions at the initiation of infection. Mol Microbiol 2000; 37(2): 345-55.
85. Loessner MJ. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 2005; 8(4): 480-87.
86. Sanz JM, Garcia P, Garcia JL. Construction of a multifunctional pneumo-coccal murein hydrolase by module assembly. Eur J Biochem 1996; 235(3): 601-605.
87. Lopez R, Garcia E, Garcia P, Garcia JL. The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? Microb Drug Resist 1997; 3(2): 199-211.
88. Pritchard DG, Dong S, Baker JR, Engler JA. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 2004; 150(Pt 7): 2079-87.
89. Huard C, Miranda G, Wessner F, Bolotin A, Hansen J, Foster SJ, Chapot-Chartier MP. Characterization of AcmB, an N-acetylglucosaminidase autolysin from Lactococcus lactis. Microbiology 2003; 149(Pt 3): 695-705.
90. Bateman A and ND Rawlings. The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolases. Trends Biochem Sci 2003; 28: 234-7.
91. Rigden, D.J., Jedrzejas, M.J. and Galperin, M.Y. Amidase domains from bacterial and phage autolysins define a family of gamma-D,L-glutamate-specific amidohydrolases. Trends Biochem Sci 2003; 28: 230-234.
92. Loessner MJ, Kramer K, Ebel F, Scherer S. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 2002; 44(2): 335-49.
93. Whisstock JC, Lesk AM. SH3 domains in prokaryotes. Trends Biochem Sci 1999; 24(4): 132-33.
94. Ponting CP, Aravind L, Schultz J, Bork P, Koonin EV. Eukaryotic signalling domain homologues in archaea and bacteria. Ancient ancestry and horizontal gene transfer. J Mol Biol 1999; 289(4): 729-45.
95. Low LY, Yang C, Perego M, Osterman A, Liddington RC. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem 2005; 280(42): 35433-39.
96. Navarre WW, Ton-That H, Faull KF, Schneewind O. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-glycine endopeptidase activity. J Biol Chem 1999; 274(22): 15847-56.
97. Yokoi KJ, Kawahigashi N, Uchida M, et al. The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage varphiWMY: cloning, sequencing, expression, and mutational analysis in Escherichia coli. Gene 2005; 351: 97-108.
98. Morita M, Tanji Y, Orito Y, Mizoguchi K, Soejima A, Unno H. Functional analysis of antibacterial activity of Bacillus amyloliquefaciens phage endolysin against Gram-negative bacteria. FEBS Lett 2001; 500(1-2): 6-9.
99. Donovan DM, Dong S, Garrett W, Rousseau GM, Moineau S, Pritchard DG. Peptidoglycan hydrolase fusions maintain their parental specificities. Appl Environ Microbiol 2006; 72(4): 2988-96.
100. Donovan, DM, Lardeo, M, Foster-Frey, J. Lysis of Staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. FEMS Microbiol Lett 2006; 265(1): 133-39.
101. Stojkovic, E., Rothman-Denes, L.B.: WO 05108563 (2005).
102. Fischetti VA. Novel method to control pathogenic bacteria on human mucous membranes. Ann N Y Acad Sci 2003; 987: 207-14.
103. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005; 13(10): 491-6.
104. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418(6900): 884-89.
105. Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B Streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005; 49(1): 111-117.
106. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98(7): 4107-12.
107. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P; Spanish Pneumococcal Infection Study Network. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52(6): 967-73.
108. Kerr DE, Plaut K, Bramley AJ, Williamson CM, Lax AJ, Moore K, Wells KD, Wall RJ. Lysostaphin expression in mammary glands confers protection against Staphylococcal infection in transgenic mice. Nat Biotechnol 2001; 19(1): 66-70.
109. Wall RJ, Powell AM, Paape MJ, et al. Genetically enhanced cows resist intramammary Staphylococcus aureus infection. Nat Biotechnol 2005; 23(4): 445-51.
110. Sass P, Bierbaum G. Lytic activity of recombinant phage {phi}11 and {phi}12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol 2006; [Epub ahead of print].
111. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71(11): 6199-6204.
112. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49(11): 4789-92.
113. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98(7): 4107-12.
114. Zimmer, M., Loessner, M., Morgan, A.J.: WO03066845 (2003).
115. Gasson, M.J.: US 20006083684 (2000).
116. Pritchard, D.G., Baker, J.: EP1546175 (2005).
117. Delisle, A.: US 20056955893 (2005).
118. Fischetti, V., Loomis, L.: US 20046733749 (2004).
119. Fischetti, V., Loomis, L.: US 20026399098 (2002).
120. Fischetti, V., Loomis, L.: US 20046685937 (2004).
121. Fischetti, V., Loomis, L.: US 20067014850 (2006).
122. Fischetti, V., Loomis, L.: US 20006056955 (2000).
123. Fischetti, V., Loomis, L.: US 20067141241 (2006).
124. Fischetti, V., Loomis, L.: US 20067063837 (2006).
125. Fischetti, V., Loomis, L.: US 20046737079 (2004).
126. Fischetti, V., Loomis, L.: US 200400766241A1 (2004).
127. Ueda T, Yamada H, Aoki H, Imoto T. Effect of chemical modifications of tryptophan residues on the folding of reduced hen egg-white lysozyme. J Biochem (Tokyo) 1990; 108(5): 886-92.
128. Thammasirirak S, Torikata T, Takami K, Murata K, Araki T. Purification and characterization of goose type lysozyme from cassowary (Casuarius casuarius) egg white. Biosci Biotechnol Biochem 2001; 65(3): 584-92.
129. Fastrez J. Phage lysozymes EXS 1996; 75: 35-64.
130. Lyne JE, Carter DC, He XM, Stubbs G, Hash JH. Preliminary crystallographic examination of a novel fungal lysozyme from Chalaropsis. J Biol Chem 1990; 265(12): 6928-30.
131. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, Peschel A, Gotz F. Influence of wall teichoic acid on lysozyme resistance in Staphylococcus aureus. J Bacteriol 2007; 189(1): 280-3.
132. Kiczka Witold; PL0190645B1 (2005).
133. Yu, L., Fu, Q., Zhao, Y., Zhang, H., Bi, A.: US 20036660512 (2003).
134. Yu, L., Zhao, Y., Hu, P., Tang, L., Zhao, S.: US20056943244 (2005).
135. Yu, L., Fu, Q., Zhao, Y., Zhang, H., Bi, A.: US20046743617 (2004).
136. Hua, Z.: CN1709503A (2005).
137. Filatov, V.N., and Ryltsev, V.V.: WO06031142A1 (2006).
138. An, M.: WO06079288A1 (2006).
139. An, M.: WO05120555A1 (2005).
140. Kolos, E.: US20036932966 (2003).
141. Veronesi, P.A., Rodriguez, P.E.A.: US20067012062 (2006).
142. An, M.: WO05120556A1 (2005).
143. Hua, A. Z.: CN1227028C (2005).
144. Berthet, F.X., Vayreda Casadevall, F., Sanz M. C., Llop Garcia T., Mor Olle, A.: US20060063149A1 (2006).
145. Browder, H.P., W.A. Zygmunt, J. R. Young, and P.A. Travormina. Lysostaphin: ezymatic mode of action. Bioochem BioPhys Res Comm 1965; 19: 383-389.
146. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 2005; 54(3): 191-200.
147. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003; 47(11): 3407-14.
148. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 2000; 41(6): 1432-7.
149. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 1999; 43(7): 1754-5.
150. Bhakta M, Arora S. and Bal M. Intraspecies transfer of a chloramphenicol-resistance plasmid of staphylococcal origin. Indian J Med Res 2003; 117: 146-51.
151. Cisani G, Varaldo PE, Grazi G. and Soro O. High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme. Antimicrob Agents Chemother 1982; 21: 531-5.
152. McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis. Curr Eye Res 2006; 31(3): 225-30.
153. Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42(6): 1355-60.
154. Oldham ER, Daley MJ. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J Dairy Sci 1991; 74(12): 4175-82.
155. Sears, P.M., Smith, B.S., Pollak, J., Gusik, S.N. and Blackburn, P., Lysostaphin efficacy for treatment of Staphylococcus aureus intramammary infection. J Dairy Sci 1988; 71 (Suppl. 1): 244.
156. Schaffner W, Melly MA, Koenig MG. Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J Biol Med 1967; 39(4): 230-44.
157. Dehart HP, Heath HE, Heath LS, Leblanc PA, Sloan GL. The Lysostaphin Endopeptidase Resistance Gene (epr) Specifies Modification of Peptido-glycan Cross Bridges in Staphylococcus simulans and Staphylococcus aureus. Appl Environ Microbiol 1995; 61(7): 2811.
158. Thumm G, Gotz F. Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol Microbiol 1997; 23(6): 1251-65.
159. Sugai M, Fujiwara T, Komatsuzawa H, SuginakaH. Identification and molecular characterization of a gene homologous to epr (endopeptidase resistance gene) in Staphylococcus aureus. Gene 1998; 224(1-2): 67-75.
160. Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysosta-phin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 200; 45(5): 1431-7.
161. Grundling A, Missiakas DM, and Schneewind O. Staphylococcus aureus mutants with increased lysostaphin resistance. J Bacteriol 2006; 188: 6286-97.
162. Shaw LN, Golonka E, Szmyd G, Foster SJ, Travis J, Potempa J. Cytoplasmic control of premature activation of a secreted protease zymogen: deletion of staphostatin B (SspC) in Staphylococcus aureus 8325-4 yields a profound pleiotropic phenotype. J Bacteriol 2005; 187(5): 1751-62.
163. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003; 47(5): 589-97.
164. Shaw L, Golonka E, Potempa J, Foster SJ. The role and regulation of the extracellular proteases of Staphylococcus aureus. Microbiology 2004; 150(Pt 1): 217-28.
165. Bera A, Herbert S, Jakob A, Vollmer W, Gotz F. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol 2005; 55(3): 778-87.
166. Lichenstein HS, Hastings AE, Langley KE, et al. Cloning and nucleotide sequence of the N-acetylmuramidase M1-encoding gene from Streptomyces globisporus. Gene 1990; 88(1): 81-6.
167. Rau A, Hogg T, Marquardt R, Hilgenfeld R. A new lysozyme fold. Crystal structure of the muramidase from Streptomyces coelicolor at 1.65 A resolution. J Biol Chem 2001; 276(34): 31994-9.
168. Amano K, Williams JC. Peptidoglycan of Legionella pneumophila: apparent resistance to lysozyme hydrolysis correlates with a high degree of peptide cross-linking. J Bacteriol 1983; 153(1): 520-6.
169. Deckers D, Masschalck B, Aertsen A, et al. Periplasmic lysozyme inhibitor contributes to lysozyme resistance in Escherichia coli. Cell Mol Life Sci 2004; 61(10): 1229-37.
170. Hewitt LF. Effect of lysozyme on the oxidation-reduction potentials of M. lysodeikticus cultures. Biochem J 1931; 25(5): 1452-7.
171. Loeffler JM, Nelson D. and Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2.
172. Connerton, I.F.: US20060222632A1 (2006).
173. Harris, D.L., Lee, N.: US20036656463 (2003).
174. Loomis, L., Fischetti, V.: WO05077046A2 (2005).
175. Bramley, A.J., Plaut, K.I, Kerr, D.: US20067091332 (2006).
176. Cottingham, I.R., McCreath, G.E.: US20067045677 (2006).
177. Fischetti, V., Loomis, L.: CA2513571A1 (2004).
178. Nelson, D., Fischetti, V.: US20026608187 (2002).
179. Loomis, L.: WO010119385A3 (2001).
180. Fischetti, VA.: US20060159671A1.
181. Fischetti, V., Loeffler, J.: EP1585478A2; WO04058182 (2004).
182. Climo, M., Murphy, E., Archer, G.: US20067078377 (2006).
183. Walsh TR. Combinatorial genetic evolution of multiresistance. Curr Opin Microbiol 2006; 9(5): 476-82.
184. Shteyngart, B.: US20050271645A1 (2005).
185. Cantor, J.-O., Shteyngart, B.: US20046776989 (2004).
186. Harper, D., Hawkins, C., Soothill, J.: WO05009451 (2005).
187. Molnarne-Kahah, I.: US20056949241 (2005).
188. Huang, N., Huang, J., Bethell, D.R.: US20067138150 (2006).
189. Lim, D.J., Lee, H.-Y., Webster, P., Andalibi, A., Li, J.-D., Ganz, T.: US 2004 6716813 (2004); US20067060764 (2006).
190. Smith, S.R., Ritchie, S. J., Zhang, G.: US20050266050A1 (2005).